PDS 0203
Alternative Names: Coronavirus vaccine - PDS Biotechnology; PDS-0203; Versamune-CoV2-FCLatest Information Update: 28 May 2024
At a glance
- Originator Farmacore; PDS Biotechnology Corporation
- Class COVID-19 vaccines; Peptide vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Brazil (Parenteral)
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 27 Aug 2021 Farmacore and Hospital do Coracao withdraw a phase I/II trial prior to enrolment for COVID-2019 infections (Prevention) in Brazil due to collaborator's request (NCT05016934)